MedPlus Health Services Limited reported a strong performance for the second quarter of fiscal year 2027 (Q2 FY27), with revenue increasing by 21.3% year-over-year to ₹20,371 million. The company also saw a substantial 50.7% jump in operating EBITDA sequentially to ₹981.1 million. The number of stores grew by 166 net additions in the quarter, reaching a total of 5,642 stores by September 30, 2026.
MedPlus Health Reports Robust Q2 FY27 Performance
MedPlus Health Services Limited announced its financial results for the second quarter ended September 30, 2026, showcasing significant growth across key metrics. Revenue for Q2 FY27 reached ₹20,371 million, marking a substantial 21.3% increase compared to ₹16,793 million in the same quarter of the previous year (Q2 FY26). Sequentially, revenue grew by 8.4% from ₹18,796 million in Q1 FY27.
EBITDA and Profitability Gains
The company’s operating EBITDA saw a remarkable surge, growing by 10.7% year-over-year to ₹981.1 million in Q2 FY27. More impressively, operating EBITDA increased by 50.7% on a quarter-over-quarter basis from ₹651.2 million in Q1 FY27. The operating EBITDA margin stood at 4.8% for the quarter.
Store Network Expansion
MedPlus Health continued its aggressive store expansion strategy. In Q2 FY27, the company added a net of 166 stores, bringing the total store count to 5,642 stores as of September 30, 2026. This includes 219 gross openings and 53 closures during the quarter. The company’s presence spans across 13 states and 1 union territory.
Key Financial Highlights (Q2 FY27 vs. Q2 FY26)
- Revenue: ₹20,371 million (up 21.3%)
- Gross Margin: ₹5,108.5 million (up 16.3%)
- Operating EBITDA: ₹981.1 million (up 10.7%)
- PAT: ₹560.7 million (up 1.0%)
First Half FY27 Performance
For the first half of fiscal year 2027 (H1 FY27), revenue grew by 21.6% year-over-year to ₹39,167 million. Pharmacy operating EBITDA for H1 FY27 was ₹1,473 million, while the company operating EBITDA stood at ₹1,632 million.
Store Level Performance
Stores operating for more than 12 months demonstrated healthy performance, with a revenue growth of 13.2% over Q2 FY26. These older stores maintained a Store Level EBITDA margin of 11.7% and an operating ROCE of 72.0%.
Balance Sheet Snapshot
As of September 30, 2026, the company’s key balance sheet items include PPE and CWIP of ₹3,818.6 million, Inventories of ₹15,210.9 million, and Cash of ₹4,621.5 million. Liabilities included Trade payables of ₹3,641.6 million.
Source: BSE
